|
| Educate and Communicate... |
PharmaVOICE produced white papers are marketing/sales documents that offer meaningful content and value to potential customers by providing unbiased information and analysis regarding a business concept or challenge.
Let PharmaVOICE help bring your knowledge and expertise to your customer base. With a pulse on the trends and challenges impacting the varying sectors of the industry, we can produce and distribute your white paper to a select audience to ensure your message is on target and delivered to the right people.
For more information on engaging PharmaVOICE to publish or market your white paper, contact Marah Walsh, mwalsh@pharmavoice.com.
|
|
 |
 |
| |
|

|
|
Five-Part Series on Marketing Excellence
Date Posted: 11/14/2008 Sponsored by: IMS
|
The following interviews are part of a Five-Part Series on Marketing Excellence, which draws on landmark IMS research on more than 3,000 new product launches and analysis of 50 in-line brands spanning 10 chronic retail markets. Each offers insights from an IMS expert on best practices for a different aspect of launch and brand management. Taken together, the discussions present an IMS perspective on a range of strategies and techniques for enhancing commercial effectiveness.
Ensuring Launch Success: Payer and Prescriber Considerations in
Today's Evolving Market
Thought Leader: Sarah Rickwood, Senior Principal, IMS
|
Fresh Approaches to Launch Success: Implications from an
IMS Study of 3,000+ Brands
Thought Leader: Robert Harold, Senior Principal, IMS
|
Winning in the Dynamic Market: Novel Approaches for
Commercial Planning and Implementation
Thought Leader: Lisa Morris, Global APLD Services, IMS
|
The Dynamic Market: Why It's the Most Important Area of Focus for Your Brand
Thought Leader: Robert Harold, Senior Principal, IMS
|
Changing the Game: New Opportunities in the Dynamic Market
Thought Leader: Lisa Morris, Global APLD Services, IMS
|
|

|
Changing the Debate on Healthcare Costs in the U.S.: The Triple Solution
for Lower Cost, Better Quality Healthcare
Date Published: 9/17/2008
Provided by: Michael Pucci, VP, External Advocacy, GlaxoSmithKline
|
This white paper and powerpoint presentation examine the cost of chronic disease on the healthcare system and provides several sound solutions to reduce rising healthecare costs: prevention, intervention, and innovation.
_____________________________________________________________________
The Asheville Project: A Special Supplement on How Pharmaceutical Care
Produced Successful Outcomes in Diabetes Patients in One North Carolina City
Date Published: 9/17/2008
Provided by: Michael Pucci, VP, External Advocacy, GlaxoSmithKline
|
This special supplement discusses how pharmacy leaders in North Carolina demonstrated the benefit of pharmaceutical care provided by pharmacists in a community-based initiative with a self-insured employer.
_____________________________________________________________________
How Patient Journey Marketing™ Delivers More Value
to Your Customers and Your Bottom Line
Date Published: 7/8/2008
Sponsored by: Cramer
|
In this whitepaper, you will learn that the value of Patient Journey Marketing™ is to create a Right Message, Right Time, Right Placement approach so that communications engage the patient meaningfully, and most importantly, when the patient is ready and able to hear and take action. Patient Journey Marketing™ can result in better patient outcomes. It strengthens retention and builds loyalty. It can lower associated healthcare costs by creating better compliance. You may also listen to the podcast below — Patient Journey Marketing™ and the Power of Video.
_____________________________________________________________________
Enhancing Global Market Access Strategies with Named Patient Programs
Date Published: 4/22/2008
Sponsored by: IDIS
|
As part of a company's market development activities, learn how named patient programs an help overcome the barriers often encountered during market development and can help encourage uptake of the drug when its launched. Named patient programs can also be used to provide access to drugs to patients who do not qualify for inclusion in a clinical trial, in geographies where a formal launch is not planned, or where a sales infrastructure doesnt exist or wont be put into place.
_____________________________________________________________________
Getting SaaSy In Pharma: How SaaS CRM Technology Offers a Lifeline
to Today's Beleaguered Pharmaceutical Companies.
Date Published: 5/6/2008
Sponsored by: VerticalsOn Demand
|
Learn why Software as a Service (SaaS) is the answer to a new way of delivering advanced sales-centric applications. Because SaaS technology is built on a multitenant architecture,it allows software vendors to provide applications that are flexible, fast, specialized, and much less expensive to deploy and maintain. The paper discusses the inherent problems facing the industry, defines SaaS in detail, and shows how this new technology can help pharmaceutical companies increase revenue and market share.
_____________________________________________________________________
Insights into Asian Markets and Consumers
Date Published: 10/1/2007
Sponsored by: TNS Healthcare
|
Learn more about the new Asian consumer with an in-depth presentation on
changing consumer trends and values. Discover the differences among Asian
markets and get a detailed profile of consumers in key Asian countries.
This information can be a powerful tool in helping you understand your
opportunities and position your products most effectively across Asia.
_____________________________________________________________________
Managing Access to Innovative Drugs Beyond U.S. Borders
Date Published: 2/5/2008
Sponsored by :IDIS
|
This whitepaper provides an overview of the basics of a Named Patient Program, the medical and regulatory implications, recommended timing for putting a program in place, and the benefits of partnering with organizations that specialize in launching and operating such programs.
|
|
_____________________________________________________________________
Precommercial Marketing and Planning:
Laying the Ground Work for Future Success
Date Published: 10/25/2007
Sponsored by: L3 Healthcare Marketing |
This whitepaper provides details on how to develop an Informed View of the Market for your brand during the pre-commercialization phase. The discussion covers the risks for not doing so, the benefits of a prelaunch strategy, and the tactics for ultimate success.
|
|
Making a Case for a Blended Solution:
Build, Buy, Blend: A Range of Options for Sales Training
Date Published: 6/12/2007
Sponsored by: NXLevel Solutions Inc. |
Discover how moving to a blended build/buy training model — one that encompasses a combination of customized content, developed by credible experts, and off-the-shelf functionality — can improve your learning processes.
|
|
Increasing Clinical Trial Data Management Efficiencies by Utilizing a Satellite Office Model
Date Published: 3/14/2007
Sponsored by: ReSearch Pharmaceutical Services, Inc. (RPS) |
Discover how moving from a traditional CRO outsourcing model to a Satellite Office resourcing model can help your clinical data management teams lower trial costs; improve efficiencies and manageability; be more flexible; and reduce timelines.
|
|
Performance Management in Clinical Research
Date Published: 2/21/2007
Sponsored by: Cognos |
Large and small pharmaceutical and biotech companies today are seriously questioning traditional approaches to product development. Legacy products are quickly facing expiring patents, and the pipeline of blockbuster drugs is struggling to replace profits. The current regulatory environment and new technology have created a crisis in R&D productivity. The current reality demands greater management insight in order to create more efficient, flexible and effective clinical processes. This is the promise of Clinical Performance Management.
|
|